摘要
目的探讨利拉鲁肽对2型糖尿病(T2DM)合并肥胖患者血清趋化素和胰岛素抵抗(IR)的影响。方法连续性收录80例肥胖T2DM患者,随机分为利拉鲁肽组(40例)和二甲双胍组(40例)。分别于入组时和治疗后3个月检测血清趋化素水平和IR相关指标[稳态模型IR指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)、胰岛素曲线下面积(INS_(AUC))、血糖曲线下面积(PG_(AUC)),以及早期胰岛素分泌功能指数(ΔI30/ΔG30)]。结果经过3个月治疗后,利拉鲁肽组患者HOMA-IR、PG_(AUC)和趋化素水平明显下降(P<0.05),HOMA-β和ΔI30/ΔG30水平明显上升(P<0.05)。组间比较可见,利拉鲁肽组患者HOMA-IR、PG_(AUC)和趋化素水平明显低于二甲双胍组(P<0.05),而HOMA-β水平明显高于二甲双胍组(P<0.05)。利拉鲁肽干预与ΔHOMA-IR和Δ趋化素呈负相关(r分别为-0.665、-0.699,P<0.05),与ΔHOMA-β(r=0.635,P<0.05)呈正相关。结论利拉鲁肽干预治疗可能通过降低血清趋化素水平进而改善肥胖T2DM患者IR程度。
Objective To investigate the influence of liraglutide on serum chemerin level and insulin resistance in the patients with type 2 diabetes mellitus（T2DM） complicating obesity. Methods Consecutive 80 T2DM patients with obesity were enrolled in this study and randomly divided into the liragluted group（n = 40） and metformin group（n= 40）. The serum chemerin level and IR related indexes were detected at the beginning of grouping and 3 months after treatment in the two groups,including the homeostasis model assessment of insulin resistance（HOMA IR）, HOMA β cell function index（HOMA-β）, area under the curve of insulin （INSAUC） ,area under the curve of blood glucose（PGAUC） and early insulin secretion index（△130/△G30）. Results The levels of HO- MA-IR,PGAUC and chemerin level after 3-months treatment in the liraglutide group were significantly decreased（P〈0.05）, while HOMA-β and △130/△G30 level were significantly increased（P〈0.05）. The comparison between the two groups showed that HOMA-IR,PGAUC and chemerin level in the liraglutide group were significantly lower than those in the metformin group（P〈0.05）, while the HOMA-β level was significantly higher than that in the metformin group（P〈0.05）. The liraglutide intervention was negatively correlated with AHOMA-IR and Achemerin（r=-0. 665,-0. 699 ,P〈0.05） and positively correlated with △HOMA-β（r= 0. 635 ,P〈0.05）. Conclusion The liraglutide intervention therapy may improve the IR degree in T2DM patients with complicating obesity possibly by reducing serum chemerin levels.
出处
《检验医学与临床》
CAS
2017年第6期800-802,共3页
Laboratory Medicine and Clinic
关键词
利拉鲁肽
2型糖尿病
肥胖
趋化素
胰岛素抵抗
liraglutide
type 2 diabetes mellitus
obesity
chemerin
insulin resistance
